MedPath
FDA Approval

Xopenex

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
December 1, 2009
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Levosalbutamol(1.25 mg in 3 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Physicians Total Care, Inc.

Physicians Total Care, Inc.

194123980

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Xopenex

Product Details

NDC Product Code
54868-5459
Application Number
NDA020837
Marketing Category
NDA (C73594)
Route of Administration
RESPIRATORY (INHALATION)
Effective Date
December 1, 2009
Code: WDQ1526QJMClass: ACTIBQuantity: 1.25 mg in 3 mL
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT

Xopenex

Product Details

NDC Product Code
54868-4409
Application Number
NDA020837
Marketing Category
NDA (C73594)
Route of Administration
RESPIRATORY (INHALATION)
Effective Date
December 1, 2009
Code: WDQ1526QJMClass: ACTIBQuantity: 0.63 mg in 3 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT

Xopenex

Product Details

NDC Product Code
54868-6021
Application Number
NDA020837
Marketing Category
NDA (C73594)
Route of Administration
RESPIRATORY (INHALATION)
Effective Date
December 1, 2009
Code: WDQ1526QJMClass: ACTIBQuantity: 1.25 mg in 0.5 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
© Copyright 2025. All Rights Reserved by MedPath